Evidence
J Addict Dis. 2023 Jul 2:1-7. doi: 10.1080/10550887.2023.2229609. Online ahead of print.
ABSTRACT
OBJECTIVES: To describe the use of buprenorphine/naloxone micro-inductions in hospitalized patients and characterize the success rate of these inductions.
METHODS: We conducted a retrospective chart review of hospitalized patients receiving a buprenorphine/naloxone micro-induction for opioid use disorder in a tertiary care hospital from Jan 2020-Dec 2020. The primary outcome was a description of the micro-induction prescribing patterns used. The secondary outcomes were a description of the demographic characteristics of patients, the estimated frequency of withdrawal symptoms experienced by patients undergoing a micro-induction, and the overall success rate of the micro-inductions defined as retention on buprenorphine/naloxone therapy with no precipitated withdrawal experienced.
RESULTS: Thirty-three patients were included in the analysis. Three main micro-induction regimens were identified, including rapid micro-inductions (8 patients), 0.5 mg SL BID initiations (6 patients), and 0.5 mg SL daily initiations (19 patients). Twenty-four patients (73%) met the criteria for a successful micro-induction, defined as being retained in buprenorphine/naloxone therapy with no precipitated withdrawal experienced. The most common reason for micro-induction failure was patient request to discontinue buprenorphine/naloxone therapy due to perceived adverse effects or personal preference.
CONCLUSION: Buprenorphine/naloxone micro-induction in hospitalized patients resulted in a majority of patients being successfully initiated on buprenorphine/naloxone therapy without requiring opioid abstinence prior to induction. Dosing regimens were variable, and the ideal regimen remains unclear.
PMID:37394486 | DOI:10.1080/10550887.2023.2229609
Add to Google Keep
Estimated reading time: 4 minute(s)
Latest: Psychiatryai.com #RAISR4D
Cool Evidence: Engaging Young People and Students in Real-World Evidence ☀️
Real-Time Evidence Search [Psychiatry]
AI Research [Andisearch.com]
Buprenorphine/naloxone micro-induction in a tertiary care hospital: a retrospective cohort analysis
🌐 90 Days
Evidence Blueprint
Buprenorphine/naloxone micro-induction in a tertiary care hospital: a retrospective cohort analysis
☊ AI-Driven Related Evidence Nodes
(recent articles with at least 5 words in title)
More Evidence